Arformoterol
From Infogalactic: the planetary knowledge core
Systematic (IUPAC) name | |
---|---|
N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl) propan-2-yl]amino]ethyl] phenyl]formamide
|
|
Clinical data | |
AHFS/Drugs.com | monograph |
MedlinePlus | a602023 |
Licence data | US FDA:link |
Pregnancy category |
|
Legal status |
|
Routes of administration |
nebuliser |
Pharmacokinetic data | |
Protein binding | 52–65% |
Biological half-life | 26 hours |
Identifiers | |
CAS Number | 67346-49-0 |
ATC code | none |
PubChem | CID: 3083544 |
IUPHAR/BPS | 7479 |
DrugBank | DB01274 |
ChemSpider | 2340731 |
UNII | F91H02EBWT |
ChEBI | CHEBI:408174 |
ChEMBL | CHEMBL1201137 |
Chemical data | |
Formula | C19H24N2O4 |
Molecular mass | 344.405 g/mol |
|
|
(what is this?) (verify) |
Arformoterol is a long acting beta-adrenoceptor agonist drug indicated for the treatment of chronic obstructive pulmonary disease (COPD). It is sold by Sunovion, under the trade name Brovana, as a solution of arformoterol tartrate to be administered twice daily (morning and evening) by nebulization.[1]
It is the active (R,R)-enantiomer of formoterol and was approved by the United States Food and Drug Administration (FDA) on October 6, 2006 for the treatment of COPD.
References
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
External links
- Brovana website
<templatestyles src="Asbox/styles.css"></templatestyles>